Research

Energy balance

Semaglutide reduced major adverse cardiovascular events and all-cause mortality.

Semaglutide may be recommended for patients at risk of cardiovascular events.

StrongSupportsmedium confidence
Semaglutide reduced major adverse cardiovascular events and all-cause mortality.
Andreea Ciudin Mihai et al. · medRxiv · 2026

Why this rating

Based on the systematic review and meta-analysis of randomized controlled trials.

Source

A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults: 2026 Update

Andreea Ciudin Mihai et al. · medRxiv · 2026

DOI 10.64898/2026.04.19.26351196

Meta-analysisCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →